Kornimate/medical-research-clean huggingface dataset:
sgs742 in patients with mild to moderate alzheimer's disease (ad)

Conditions: Alzheimer's Disease

Summary: the purpose of this trial is to determine the effect of a new drug, sgs742, on memory and cognition in patients with mild to moderate alzheimer's disease.

sgs742 is a gaba(b) receptor antagonist. it is an orally active drug and possesses neurochemical and psychopharmacologic features that suggest it could improve memory and cognition in humans. the primary objective of the sgs742 clinical trial will be to determine the effect of sgs742 on memory and cognition in individuals diagnosed with mild to moderate alzheimer's disease. the duration of the study is 3 months with 5 clinic visits.

Eligibility criteria:
inclusion criteria: * 55 to 90 years of age * diagnosed with mild to moderate alzheimer's disease * willing caregiver * in general good health exclusion criteria: * call 1-877-my-memory and ask to be referred to a study center located near you for entry criteria information. prohibited meds: * alzheimer's medications (aricept, exelon, remydl, nemenda)

Keywords: alzheimer disease memory cognition gaba(b)receptor antagonist
serplulimab combined with chemotherapy in patients with resectable esophageal squamous cell carcinoma

Conditions: Esophageal Squamous Cell Carcinoma; Neoadjuvant Therapy

Summary: china with high incidence of esophageal cancer, the number of new cases and deaths account for about 50% of the world every year. in the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously improved, however, the mortality of esophageal squamous cell carcinoma patients was not significantly decreased. for patients with locally advanced esophageal cancer, direct surgery is not effective. it is difficult to achieve radical resection by surgery merely, and even if many patients receive surgery, they may eventually have tumor recurrence and poor survival rate. therefore, it is necessary to explore effective perioperative neoadjuvant treatment to reduce the risk of postoperative recurrence and improve the postoperative survival rate of patients. according to the reports, the expression of pd-l1 in esophageal cancer was about 41.4%. therefore, pd-1/ pd-l1 immunocheckpoint inhibitor may become a new method for the treatment of esophageal cancer. preliminary clinical results showed that immunotherapy combined with chemoradiotherapy provided a synergies antitumor effect. multiple clinical results showed that serplulimab provided higher overall response rate for advanced esophageal cancer. however, in patients with locally advanced esophageal cancer, the efficacy of serplulimab combined with chemotherapy for sequential radical surgery is still unclear. the purpose of this study is to observe and evaluate the efficacy and safety of silulimab combined with chemotherapy in the neoadjuvant therapy of resectable esophageal squamous cell carcinoma.


Eligibility criteria:
inclusion criteria: 1. signed informed consent; 2. patients age 18 to 75 years old 3. primary resectable, histologically confirmed esophageal squamous cell cancer; 4. esophageal squamous cell carcinoma the clinical stage was iia-iva (according to ajcc tnm stage, 8th edition). 5. ecog ps 0-1. 6. no distant metastasis, the diseases could be resectable assessed by thoracic oncologist; exclusion criteria: 1. with significant cardiovascular disease; 2. current treatment with anti-viral therapy or hbv; 3. female patients who are pregnant or lactating; 4. history of malignancy within 5 years prior to screening; 5. active or history of autoimmune disease or immune deficiency; 6. signs of distant metastases.

Keywords: serplulimab esophageal squamous cell carcinoma neoadjuvant treatment
quadratus lumborum block for percutaneous nephrostomy

Conditions: Nephrostomy; Complications; Upper Urinary Tract Dilatation and Obstruction; Regional Anesthesia Morbidity; Adverse Anesthesia Outcome

Summary: percutaneous nephrostomy (pcn) is one of the interventions in the radiology department in which pain control is necessary. quadratus lumborum (ql) block will be tried to limit the use of systemic analgesics and its accompanying untoward effects in those frail patients requiring pcn that is performed in the prone position.

quadratus lumborum block is a novel technique in which extension into the thoracic paravertebral space may occur. ql block would seem to be able to alleviate both somatic and visceral pain so it's expected to decrease the need for systemic sedation\\analgesia to a minimum.

Eligibility criteria:
inclusion criteria: 1. asa grade iii and iv patients, 2. ureteral obstruction due to malignancy or secondary to urinary diversion after cystectomy exclusion criteria: 1. bleeding diathesis; inr more than than 1.5 and platelet count less than 100,000/mm3. 2. untreated urinary tract infection; 3. pre-operative haemoglobin \<10 gm/dl, 4. severely co morbid patients 5. non-dilated renal collecting system 6. patient refusal to consent for the procedure.

Keywords: percutaneous nephrostomy quadtatus lumborum block cancer monitored anaesthesia care
mechanisms of human heat perception - involvement of trpa1, trpv1 and trpm3

Conditions: Pain

Summary: animal studies suggest that the ion channels trpv1, trpa1 and trpm3 are the relevant heat sensors. this study aims to validate these findings in humans.

surprisingly, it is still not fully understood how humans perceive heat pain. there are several heat-sensitive ion channels whose manipulation in animals resulted in a more or less pronounced phenotype. however, complete blockade of heat sensation in animals has only recently been achieved. in triple knockout mice lacking trpa1, trpv1 and trpm3, it was recently shown that only in the absence of all three receptors heat perception is largely abolished. although the authors were unable to elucidate the underlying mechanism of this redundancy, the redundancy appears to have evolutionary value for protection against burns. in addition, recent evidence suggests that trpv1 plays a role as a first-line defense against heat injury, i.e., that it encodes noninjurious heat injury in humans. the goal of this study is to test whether the redundant functions of trpv1, trpa1 and trpm3 observed in mice with respect to heat perception also apply to humans. more broadly, we want to understand which receptors enable humans to perceive heat pain. the study also aims to test if a chloride channel is involved in heat perception. design: cross-over study with a williams design group, 16 treatments incl. a placebo control.

Eligibility criteria:
inclusion criteria: * age between 18 and 70 years * full legal capacity to ensure an equal number of each sex in the study population, only volunteers of one sex will be included as soon as the number of subjects with the other sex has reached half of the calculated sample size. exclusion criteria: * participant of another study, ongoing or within the last 4 weeks * medication intake (except contraception) or drug abuse * female subjects: positive pregnancy test or breastfeeding * body temperature above 38°c, diagnostically verified * known allergic diseases, in particular asthmatic disorders and skin diseases, known allergic reactions to citrus fruits (but excluding food intolerances). * sensory deficit, skin disease or hematoma of unknown origin in physical examination of the test site * symptoms of a respiratory tract infection (covid-19 related criterion)

Keywords: psychophysics human physiology sensory neuron trp channels heat perception
prognosis and treatment of copd in primary care-use of biomarkers

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: this is an observational study in primary care aiming to validate biomarkers for chronic obstructive pulmonary disease (copd).


Eligibility criteria:
inclusion criteria: * 40 years old or more, * diagnosis of copd in primary care exclusion criteria: * major psychiatric illness, * inability to visit primary care doctor, * inability to understand danish language,

Keywords: chronic obstructive pulmonary disease copd
zd6474(vandetanib) + alimta combo study

Conditions: Carcinoma; Non-Small Cell Lung; Lung Cancer

Summary: the main purpose of this trial is to look to see if adding zd6474 (100 mg or 300mg tablets) to alimta chemotherapy in patients with non-small cell lung cancer is safe and will help control their symptoms and disease better than the chemotherapy alone.


Eligibility criteria:
inclusion criteria: * confirmed advanced or metastatic non-small cell lung cancer * failure of first-line chemotherapy * 1 or more measurable lesion by recist exclusion criteria: * previous chemotherapy or radiotherapy within 4 weeks * significant cardiac events, arrythmias or other cardiac conditions * unacceptable laboratory measurements

Keywords: non-small cell lung cancer lung cancer alimta vandetanib phase 1
gene expression in patients with epiretinal membranes

Conditions: Proliferative Diabetic Retinopathy

Summary: the purpose of this study was to investigate the expression of selected genes both in epiretinal membranes (erms) and peripheral blood mononuclear cells (pbmcs) from patients with primary and secondary epiretinal membranes in proliferative diabetic retinopathy. possible correlations between messenger ribonucleic acid (mrna) levels of these genes were also identified.


Eligibility criteria:
inclusion criteria: * caucasian race, * both males and females, * aged ≥ 55 years, * suffering from idiopathic erms or secondary erms in proliferative diabetic retinopathy (pdr). * presence of erm was proven in optical coherence tomography (oct) examination. exclusion criteria: * aged \< 55 years, * systemic connective tissue disease, * active inflammatory process

Keywords: idiopathic epiretinal membranes secondary epiretinal membranes
open-label study of oral cep-701 (lestaurtinib) in patients with polycythemia vera or essential thrombocytosis

Conditions: Polycythemia Vera; Essential Thrombocytosis

Summary: this is an 18-week open-label, multicenter study to evaluate the efficacy and tolerability of cep-701 (lestaurtinib) treatment in patients with polycythemia vera (pv) and patients with essential thrombocytosis (et).

this is an 18-week open-label, multicenter study to evaluate the efficacy and tolerability of cep-701 (lestaurtinib) treatment at a dosage of 80 mg bid for 18 weeks (126 days) in patients with polycythemia vera (pv) who have abnormal baseline neutrophil counts or require hydroxyurea therapy and patients with essential thrombocytosis (et) who require hydroxyurea therapy for disease control.

Eligibility criteria:
inclusion criteria: * the patient has polycythemia vera (pv) or essential thrombocytosis (et). * the patient has a detectable jak2 v617f mutation. * patients with pv have at least 1 of the following risk factors: 1. neutrophil count greater than 7000/mm3 2. receiving hydroxyurea treatment * patients with et are receiving concomitant hydroxyurea. * the patient has an ecog performance score of 0, 1, or 2. exclusion criteria: * the patient has bilirubin levels or aspartate transaminases (ast) levels within exclusionary ranges. * patient has serum creatinine concentrations within exclusionary ranges. * patient has an untreated or progressive infection. * patient has any physical or psychiatric condition that may compromise participation in the study. * has a history of venous or arterial thrombosis within 6 months. * use of hydroxyurea has been initiated or escalated in the month prior to screening. * has active gastrointestinal ulceration or bleeding. * patient has used an investigational drug within the past 30 days. * patient is being treated with anagrelide. * patient has previously taken cep-701 (lestaurtinib). * patient has hypersensitivity to cep-701 (lestaurtinib) or any component of cep-701 (lestaurtinib). * patient has received interferon within the past 30 days.
modifying pest for psoriatic arthritis screening

Conditions: Plaque Psoriasis; Psoriatic Arthritis

Summary: the purpose of this study is to assess the impact of adding two questions and pictures to the validated pest on the potential diagnosis of psa in participants with moderate-to-severe plaque pso in canada.

patients will be enrolled in the study for up to 66 days and will be asked to fill-out a psa screening questionnaire at their first dermatologist visit. patients screening positive for psa will have a second visit with a rheumatologist where a full psa diagnosis assessment will be performed. a remote 'end of study' (eos) visit will be conducted by the dermatologist to document the patient's biologic disease-modifying antirheumatic drugs (bdmards) treatment choice and status.

Eligibility criteria:
key inclusion criteria: 1. moderate-to-severe plaque pso patients who are candidates for bdmards, as per provincial reimbursement criteria 2. adult patients at the time of informed consent signature 3. patients able to understand and willing to comply with protocol requirements, instructions, and restrictions 4. residents of canada key exclusion criteria: 1. patients who have previously screened positive for psa through pest or any other screening method 2. patients who have been diagnosed with psa and/or followed by a rheumatologist 3. patients who have been diagnosed with inflammatory arthritis unrelated to psa (rheumatoid arthritis, reactive arthritis, enteropathic arthritis, axial spondyloarthritis) 4. patients treated with a bdmard for moderate-to-severe plaque pso or any other medical condition

Keywords: psoriasis psoriatic arthritis psa plaque psoriasis pso implementation science psoriasis epidemiology screening tool
a novel iron supplement for athletes: phase i

Conditions: Constipation; Diarrhea; Cramp, Abdominal; Bleeding Gastric

Summary: female endurance athletes are susceptible to iron deficiency and this can impact their exercise performance. this study is a pilot trial to assess the tolerability of a novel iron supplement prior to conducting a clinical trial on the efficacy of the developed novel iron supplement on iron status and performance.

current iron supplements on the market are commonly associated with side effects including gastrointestinal distress, nausea, vomiting, and constipation. as a solution, the investigators have developed a novel delivery system for iron supplementation that overcomes many of these limitations. the goal of this study is to assess the tolerability of the developed supplement and any associated symptoms before conducting a clinical trial on this product. participants will consume 40mg of elemental iron every second day for 14 days. participants will complete a daily survey in which they will report feelings of stress and recovery as well as gastrointestinal symptoms. additionally, participants will complete a more thorough survey of gastrointestinal symptoms at baseline, the mid-point, and the end of the study.

Eligibility criteria:
inclusion criteria: * cis-gendered female 18-25years old * bmi \<25 kg/m2 * engaging in moderate to vigorous physical activity for ≥3 hours per week exclusion criteria: * gastrointestinal issues (e.g. irritable bowel disease/syndrome) * chronic illnesses * prescription medication (including oral contraceptives) * allergies to supplement ingredients * iron supplementation in the last 3 months
extending indication for islet autotransplantation in pancreatic surgery

Conditions: Diabetes

Summary: islet autotransplantation (iat) is a therapeutic approach used to prevent pancreatogenic diabetes or to reduce the severity of diabetes after a major pancreatectomy. total pancreatectomy with iat is being used almost exclusively for treatment of chronic pancreatitis. more recently, indications other than chronic pancreatitis have been reported including iat after extended pancreatectomy performed for the resection of benign tumors of the mid-segment of the pancreas or iat after total pancreatectomy for severe abdominal trauma in this study, we study our experience with iat for the treatment of a broader population of patients undergoing pancreatic surgery including subjects with technically unfeasible or high risk pancreatic anastomosis during partial pancreatectomy and subjects undergoing completion pancreatectomy because of anastomosis leakage after pancreatoduodenectomy for nonmalignant or malignant diseases.


Eligibility criteria:
inclusion criteria: * 18 years of age * ability to provide written informed consent * fasting glycaemia \<126 mg/dl without glucose-lowering medications. exclusion criteria: * any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial * diagnosis of intraductal papillary mucinous cancer, unless the absence of multifocal lesion is demonstrated by endoscopic us * presence of multifocal or residual disease at the pancreatic margin. if a malignat disease is the reason for the surgery, 1 cm of the pancreatic remnant in proximity to the pancreatic margin will be resected and sent for immediate pathologic analysis to confirm margin negativity and to rule out multifocal tumor

Keywords: pancreatogenic diabetes autologou islet transplantation pancreas pancreatectomy
effect of different liquids intake in vasovagal reaction after whole blood donation

Conditions: Blood Donation

Summary: we compared the effect of 3 different kinds of liquids (water, oral rehydration salt 3 and white granulated sugar water) intake in vasovagal reaction after whole blood donation

vasovagal reaction is the most common type of blood donation reaction. the main cause of this reaction is the decrease of blood volume. therefore, fluid supplement before blood donation has been proved to be effective in preventing the vagal reaction after blood donation. it was proved that isotonic (sugar \& salt) drink intake before blood donation had a significant effect on reducing vasovagal reaction. however, in 2002, who recommended the new reduced osmolarity rehydration formula with better taste. oral rehydration salt 3 has been produced according to who formula with standard ingredient and easy to prepare. in addition, in guangdong culture, sugar water is regarded as a tonic, more easily accepted. so, the aim of our study was to compare the effects of 500 ml water with oral rehydration salt 3, white granulated sugar and conventional recommended water intake prior to blood donation on blood donation reaction after whole blood donation, in order to understand the effect of different liquid supplement on blood donation reaction and the willingness of blood donation again.

Eligibility criteria:
inclusion criteria:all blood donors donated whole blood in guangzhou blood center during study. - exclusion criteria:blood donors who were deferral by blood screening result and other situations. -
intravenous (iv) iron vs. no iron as the treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin therapy

Conditions: Anemia

Summary: to assess the change in hemoglobin levels when iron sucrose was added to a regimen of weekly, fixed doses of erythropoietin in patients who had or had not responded to erythropoietin therapy alone.

this was a two stage, randomized, controlled study of cancer patients undergoing or planning to undergo chemotherapy. after stage one, (where patients were exposed to an erythropoiesis stimulating agent), patients were randomized to receive either iv iron sucrose or no iron supplementation. patients were then followed to safety and efficacy endpoints.

Eligibility criteria:
inclusion criteria: * histological diagnosis of cancer * hgb \</= 10 * ongoing or planned chemotherapy * body weight \>50kg * free of active infection * karnofsky status 60% to 100% exclusion criteria: * active infection * use of multivitamins with iron within one week of entry * myelophthisic bone marrow involvement by tumor except hematologic malignancy * concurrent medical condition that would prevent compliance or jeopardize the health of the patient * use of any iv iron products within two months of study entry * blood transfusions * hypoplastic bone marrow failure state * acute leukemia * myeloproliferative syndrome * uncontrolled hypertension

Keywords: anemia cancer chemotherapy
advanced robotic training with additional degrees of freedom: towards a free-walking system

Conditions: Post Stroke Gait Training

Summary: the objective of the study is to compare a new medical devices with an established medical device for lower limb rehabilitation regarding training outcome and patient comfort / patient satisfaction (primary objective) and treatment effect (exploratory objective). primary study endpoints will be a significantly higher rated patient comfort and or patient satisfaction using the new versions, compared with the established lokomat. furthermore, muscle activity and kinematic movement patterns will be expected to show more involved muscle groups and a walking pattern involving more degrees of freedom during use of the new version compared with the established lokomat. exploratory endpoints will be a significantly stronger involvement of muscles needed for balance, more physiological walking patterns and more change on the lateral positioning of the feet due to training with the new version, compared with the established lokomat.


Eligibility criteria:
inclusion criteria: * lower extremity weakness due to stroke * minor functional impairment (mrc \< 5) * ability and willingness to participate exclusion criteria: * severe spasticity of the lower extremities * severe dementia * severe depression * any other contraindications against lokomat training * body weight \> 135 kg
the effects of t4 versus t4/t3 on psychological distress after total thyroidectomy in thyroid cancer patients

Conditions: Thyroid Cancer; Distress; Depression; Anxiety; Fatigue

Summary: the goal of this research is to compare the effects on psychological distress between t4 mono replacement group and t4/t3 combination replacement group after total thyroidectomy in thyroid cancer patients. 1. subjects: * psychologically distressed patients, such as depression, anxiety, and fatigue patient after total thyroidectomy with thyroid cancer are considered for participation. screening of distress after total thyroidectomy is used hads (hospital anxiety and depression scale) ≥ 8 for depression or anxiety, and mdasi-f (md anderson symptom inventory -fatigue) ≥ 4 for fatigue. 2. randomization: * using the table of random sampling numbers, patients assign to t4 mono replacement group or t4/t3 combination replacement group. 3. evaluation for distress: * assessment will be made baseline, 4 weeks, 12 weeks and 24 weeks to investigate change of psychological distress (depression, anxiety, and fatigue). level of distress after thyroidectomy will determine using hospital anxiety and depression scale (hads), beck depression inventory (bdi), beck anxiety inventory (bai) for depression or anxiety, and brief fatigue inventory (bfi) for fatigue.


Eligibility criteria:
inclusion criteria: 1. patient who need thyroid hormone replacement therapy after total thyroidectomy for thyroid cancer 2. hads (hospital anxiety and depression scale) ≥ 8 for depression or anxiety, or mdasi-f (md anderson symptom inventory -fatigue) ≥ 4 3. patient who maintain tsh recommendation range for tsh suppression according to ata guidelines exclusion criteria: 1. \< 19 or ≥ 70 years old 2. communication difficulties or inability to complete the necessary investigations and questionnaires 3. inability to understand purpose of the study or disagree of participation 4. past history of psychiatric treatment or diagnosis 5. lactation or pregnancy 6. past medical history of other cancer diagnosis or treatment 7. any of severe comorbid medical conditions according to asa score ≥ 3